Evidence mapPaperPMID 42451709Full record

ReviewMolecules (Basel, Switzerland)2026

Enzymatic Nanomotors Integrated with Plant Extracts: Biochemical Mechanisms, Applications, and Clinical Perspectives.

Joanna Lemanowicz, Kinga Gawlińska, Iwona Jaskulska, Emilia Leśniak, Antoni Kuczyński

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joanna LemanowiczDivision of Biochemistry, Faculty of Medicine, Bydgoszcz University of Science and Technology, Bernardyńska 6 St., 85-029 Bydgoszcz, Poland.ORCID 0000-0001-7235-3903
Kinga GawlińskaDepartment of Clinical Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0001-7015-154X
Iwona JaskulskaDepartment of Agronomy and Food Processing, Faculty of Agriculture and Biotechnology, Bydgoszcz University of Science and Technology in Bydgoszcz, 7 Kaliskiego St., 85-796 Bydgoszcz, Poland.
Emilia LeśniakDivision of Biochemistry, Faculty of Medicine, Bydgoszcz University of Science and Technology, Bernardyńska 6 St., 85-029 Bydgoszcz, Poland.
Antoni KuczyńskiDivision of Biochemistry, Faculty of Medicine, Bydgoszcz University of Science and Technology, Bernardyńska 6 St., 85-029 Bydgoszcz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzymatic nanomotors (EMNMs) represent an emerging class of intelligent nanosystems that exploit enzymatic biocatalysis to generate autonomous motion within biological environments, including complex cellular and tissue contexts within living organisms. Owing to their ability to utilize endogenous biofuels, high biocompatibility, and capacity for targeted propulsion, EMNMs have demonstrated considerable potential in diverse biomedical applications. These include targeted drug delivery, cancer therapy, diagnostics, and bioimaging, as well as the traversal of biological barriers. This review comprehensively discusses the mechanisms underlying enzyme-driven propulsion, nanomotor design strategies, and their current and prospective applications in medicine, while also addressing major challenges associated with enzymatic stability, biocompatibility, motion control, and clinical safety. Furthermore, future perspectives are highlighted, including enzyme cascade systems, intelligent nanomotor swarms, biodegradable materials, and strategies facilitating clinical translation. As a representative example of practical application, curcumin was employed as a model therapeutic agent due to its well-established anticancer, anti-inflammatory, and antioxidant properties, enabling evaluation of the nanomotors' capability for controlled, pH-responsive release of therapeutic cargo. Nanophytomedicine enhances the therapeutic efficacy of phytochemicals by improving their stability, bioavailability, and targeted delivery through nanocarrier systems. The integration of phytotherapy with nanotechnology offers promising opportunities for the development of safer and more effective therapeutic strategies.

Indexed as

EnzymesPlant ExtractsAnimalsBiocatalysisDrug Delivery SystemsHumansNanomedicineNanotechnologyEnzymesPlant Extractsenzymesnanomedicineplant extractprecision medicinetargeted drug deliverytherapeutic and catalytic nanomotors

Identifiers

PMID42451709
PMCPMC13363610

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.